158 related articles for article (PubMed ID: 28787735)
21. IL-6 serum levels are elevated in Parkinson's disease patients with fatigue compared to patients without fatigue.
Pereira JR; Santos LVD; Santos RMS; Campos ALF; Pimenta AL; de Oliveira MS; Bacheti GG; Rocha NP; Teixeira AL; Christo PP; Scalzo PL
J Neurol Sci; 2016 Nov; 370():153-156. PubMed ID: 27772747
[TBL] [Abstract][Full Text] [Related]
22. Polyneuropathy in levodopa-treated Parkinson's patients.
Szadejko K; Dziewiatowski K; Szabat K; Robowski P; Schinwelski M; Sitek E; Sławek J
J Neurol Sci; 2016 Dec; 371():36-41. PubMed ID: 27871444
[TBL] [Abstract][Full Text] [Related]
23. Risk factors and safe dosage of levodopa for wearing-off phenomenon in Chinese patients with Parkinson's disease.
Chen H; Fang J; Li F; Gao L; Feng T
Neurol Sci; 2015 Jul; 36(7):1217-23. PubMed ID: 25616444
[TBL] [Abstract][Full Text] [Related]
24. [Expression of serum GDF15 and its clinical significance in multiple myeloma patients].
Zhao N; Yang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Mar; 39(3):270-5. PubMed ID: 24748192
[TBL] [Abstract][Full Text] [Related]
25. Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation-Refractory Symptoms in Advanced Parkinson Disease.
Regidor I; Benita V; Del Álamo de Pedro M; Ley L; Martinez Castrillo JC
Clin Neuropharmacol; 2017; 40(3):103-107. PubMed ID: 28452905
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of salivary heme oxygenase-1 as a potential biomarker of early Parkinson's disease.
Song W; Kothari V; Velly AM; Cressatti M; Liberman A; Gornitsky M; Schipper HM
Mov Disord; 2018 Apr; 33(4):583-591. PubMed ID: 29488275
[TBL] [Abstract][Full Text] [Related]
27. A new diagnostic indication device of a biomarker growth differentiation factor 15 for mitochondrial diseases: From laboratory to automated inspection.
Koga Y; Povalko N; Inoue E; Ishii A; Fujii K; Fujii T; Murayama K; Mogami Y; Hata I; Ikawa M; Fukami K; Fukumoto Y; Nomura M; Ichikawa K; Yoshida K
J Inherit Metab Dis; 2021 Mar; 44(2):358-366. PubMed ID: 32965044
[TBL] [Abstract][Full Text] [Related]
28. Associations Between Serum GDF15 Concentrations, Muscle Mass, and Strength Show Sex-Specific Differences in Older Hospital Patients.
Herpich C; Franz K; Ost M; Otten L; Coleman V; Klaus S; Müller-Werdan U; Norman K
Rejuvenation Res; 2021 Feb; 24(1):14-19. PubMed ID: 32475214
[TBL] [Abstract][Full Text] [Related]
29. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
Goetz CG; Stebbins GT; Blasucci LM
Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
[TBL] [Abstract][Full Text] [Related]
30. Serum miR-221 serves as a biomarker for Parkinson's disease.
Ma W; Li Y; Wang C; Xu F; Wang M; Liu Y
Cell Biochem Funct; 2016 Oct; 34(7):511-515. PubMed ID: 27748571
[TBL] [Abstract][Full Text] [Related]
31. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
[TBL] [Abstract][Full Text] [Related]
32. Plasma GDF15 level is elevated in psychosis and inversely correlated with severity.
Kumar P; Millischer V; Villaescusa JC; Nilsson IAK; Östenson CG; Schalling M; Ösby U; Lavebratt C
Sci Rep; 2017 Aug; 7(1):7906. PubMed ID: 28801589
[TBL] [Abstract][Full Text] [Related]
33. Baseline Plasma C-Reactive Protein Concentrations and Motor Prognosis in Parkinson Disease.
Umemura A; Oeda T; Yamamoto K; Tomita S; Kohsaka M; Park K; Sugiyama H; Sawada H
PLoS One; 2015; 10(8):e0136722. PubMed ID: 26308525
[TBL] [Abstract][Full Text] [Related]
34. The relation of testosterone levels with fatigue and apathy in Parkinson's disease.
Kenangil G; Orken DN; Ur E; Forta H; Celik M
Clin Neurol Neurosurg; 2009 Jun; 111(5):412-4. PubMed ID: 19131155
[TBL] [Abstract][Full Text] [Related]
35. Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells.
Le WD; Rowe DB; Jankovic J; Xie W; Appel SH
Arch Neurol; 1999 Feb; 56(2):194-200. PubMed ID: 10025424
[TBL] [Abstract][Full Text] [Related]
36. Correlation between the Movement Disorders Society Unified Parkinson's Disease rating scale (MDS-UPDRS) and the Unified Parkinson's Disease rating scale (UPDRS) during L-dopa acute challenge.
Merello M; Gerschcovich ER; Ballesteros D; Cerquetti D
Parkinsonism Relat Disord; 2011 Nov; 17(9):705-7. PubMed ID: 21784692
[TBL] [Abstract][Full Text] [Related]
37. The role of sigma-receptors in levodopa-induced dyskinesia in patients with advanced Parkinson disease: a positron emission tomography study.
Nimura T; Ando T; Yamaguchi K; Nakajima T; Shirane R; Itoh M; Tominaga T
J Neurosurg; 2004 Apr; 100(4):606-10. PubMed ID: 15070112
[TBL] [Abstract][Full Text] [Related]
38. The impact of remacemide hydrochloride on levodopa concentrations in Parkinson's disease. Parkinson Study Group.
Clin Neuropharmacol; 1999; 22(4):220-5. PubMed ID: 10442252
[TBL] [Abstract][Full Text] [Related]
39. Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease.
Perez-Lloret S; Negre-Pages L; Damier P; Delval A; Derkinderen P; Destée A; Meissner WG; Schelosky L; Tison F; Rascol O
JAMA Neurol; 2014 Jul; 71(7):884-90. PubMed ID: 24839938
[TBL] [Abstract][Full Text] [Related]
40. Effects of levodopa on retina in Parkinson disease.
Sen A; Tugcu B; Coskun C; Ekinci C; Nacaroglu SA
Eur J Ophthalmol; 2014; 24(1):114-9. PubMed ID: 23828323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
